ALLOCETRA-OTS not checked

Enlivex Therapeutics Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.”In the company’s words, NCT04922957 on ClinicalTrials.gov
Tested for
Covid19 (2 trials), Peritoneal Metastases (2 trials), Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute, Cholangitis Acute, Intraabdominal Infections and 2 more
Main trialPhase 2
“This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10\^9 cells vs placebo (1:1) in adult hospitalized patients with severe or critical Coronavirus Disease 2019 (COVID-19) with associated acute respiratory distress syndrome (ARDS). Patients will be followed for efficacy and safety for 6 months. The trial will include periodic and ad-hoc DSMB review during the study period.”In the company’s words, NCT04922957 on ClinicalTrials.gov
Other names
Cell based therapy · Apoptotic cells

Other drugs for Covid19

All 43 drugs for Covid19

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Terminated 1 Apr 2022 A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
Phase 2Completed 12 Jan 2024 A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Phase 1/2Terminated 14 Mar 2024 Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis
Phase 1/2Terminated 15 Apr 2024 A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Phase 1Unknown Sep 2022 Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ALLOCETRA-OTS

Following is part of Solo: you see every change to ALLOCETRA-OTS the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in